BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join

  Latest News

Neuralink Begins UK Clinical Trial of Brain Implant for People with Paralysis

by BiopharmaTrend   •   July 31, 2025  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

# Clinical Trials   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

Neuralink, Elon Musk’s brain computer interface (BCI) developing company, has launched its first clinical trial in the UK to evaluate the safety and functionality of its N1 brain-computer interface (BCI) implant. The feasibility study, called GB-PRIME, will enroll up to seven participants with severe neurological conditions—such as spinal cord injury or motor neurone disease—that impair the ability to use digital devices. The trial is being conducted at two sites: University College London Hospitals (UCLH) and Newcastle Upon Tyne Hospitals.

#advertisement
AI in Drug Discovery Report 2025

See also: Beyond Neuralink: The Diverse Landscape of Brain-Computer Interfaces

The N1 implant is a wireless, fully implantable BCI designed to allow users to control external devices, such as smartphones or computers, using brain activity alone. The device captures neural signals through over 1,000 electrodes embedded in ultra-thin threads, each finer than a human hair. These are precisely placed within key areas of the brain using Neuralink’s R1 surgical robot under the supervision of a neurosurgeon.

Image: Neuralink’s R1 surgical robot

Participants will undergo surgery at UCLH’s National Hospital for Neurology and Neurosurgery, with trial oversight provided by researchers at UCL and Newcastle University. The trial has been approved by UK regulatory bodies, including the Medicines and Healthcare products Regulatory Agency (MHRA), the Health Research Authority (HRA) and Health and Care Research Wales (HCRW), and a national ethics committee.

Image: Neuralink's N1 implant structure

GB-PRIME follows similar trials in the US, Canada, and the UAE, where at least nine participants have already received implants. In the UK, eligible participants include individuals over 22 years old living with paralysis caused by conditions such as spinal cord injury and amyotrophic lateral sclerosis (ALS).

At this time, the GB-PRIME study will not include the use of BCI for robotic arm control. Interested individuals can register at neuralink.com/trials.

Topics: Clinical Trials   

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.